{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:05:51Z","timestamp":1784279151963,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009594","name":"University of P\u00e9cs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009594","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Non-steroidal anti-inflammatory agents are widely used for their analgesic, anti-inflammatory, and antipyretic effects, and a prominent representative of the drug family, diclofenac has recently been proposed for cancer therapy. However, overdose of diclofenac has also been reported to cause liver toxicity, whereas olaparib, a widely used antineoplastic poly (ADP-ribose) polymerase inhibitor, is known for its mitochondria-mediated cytoprotective properties. In this study, we used HepG2 human hepatocellular carcinoma cells, which retain various characteristics of hepatocytes, to study the interaction between these two drugs. We found that diclofenac caused a 20\u201350% decrease in the viability and invasive growth of the cells, which olaparib ameliorated by approximately 50%. Additionally, olaparib reversed diclofenac-induced mitochondrial depolarization as demonstrated by JC-1 fluorescence microscopy and flow cytometry. Furthermore, although not possessing significant free-radical scavenging properties according to the cell-free Fenton reaction system, olaparib also mitigated diclofenac-induced reactive oxygen species production and apoptosis-inducing factor-mediated parthanatos. Using the Seahorse cellular respirometer, we showed that diclofenac shifted the energy production of HepG2 cells toward oxidative phosphorylation by approximately 40%, whereas olaparib reversed this effect, suggesting that the two drugs may have opposite effects on the metabolic reprogramming of cancer cells. Therefore, further studies are needed before considering their combined use for oncological applications. Additionally, we demonstrated that complex I inhibition and preservation of cellular NAD\n                    <jats:sup>+<\/jats:sup>\n                    pool are unlikely to be involved among the mechanisms of olaparib\u2019s protective effect.\n                  <\/jats:p>","DOI":"10.1007\/s11010-026-05581-3","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:20:35Z","timestamp":1780395635000},"page":"3031-3043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Olaparib alleviates diclofenac-induced toxicity in HepG2 cells via modulation of oxidative stress and mitochondrial functions"],"prefix":"10.1007","volume":"481","author":[{"given":"Mohamed","family":"Maki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola B.","family":"Vantus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Koszegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliz","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omeralfaroug","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysaa A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor Z.","family":"Janosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1906-4333","authenticated-orcid":false,"suffix":"Jr.","given":"Ferenc","family":"Gallyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"2","key":"5581_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40122-018-0100-2","volume":"7","author":"F Atzeni","year":"2018","unstructured":"Atzeni F, Masala IF, Sarzi-Puttini P (2018) A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac. Pain Ther 7(2):163\u2013177. https:\/\/doi.org\/10.1007\/s40122-018-0100-2","journal-title":"Pain Ther"},{"issue":"1","key":"5581_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/antiox13010017","volume":"13","author":"SR Kim","year":"2023","unstructured":"Kim SR, Park JW, Choi YJ et al (2023) Mitochondrial H(2)O(2) Is a Central Mediator of Diclofenac-Induced Hepatocellular Injury. Antioxid (Basel) 13(1):17. https:\/\/doi.org\/10.3390\/antiox13010017","journal-title":"Antioxid (Basel)"},{"key":"5581_CR3","doi-asserted-by":"publisher","first-page":"36519","DOI":"10.1021\/acsomega.2c04396","volume":"41","author":"P Basist","year":"2022","unstructured":"Basist P, Khan MU, Jan B et al (2022) Metabolite Profiling and Nephroprotective Potential of the Zea mays L. Silk Extract against Diclofenac-Induced Nephrotoxicity in Wistar Rats. ACS Omega 41:36519\u201336534. https:\/\/doi.org\/10.1021\/acsomega.2c04396","journal-title":"ACS Omega"},{"key":"5581_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ijcard.2016.08.233","volume":"223","author":"R Ghosh","year":"2016","unstructured":"Ghosh R, Goswami SK, Feitoza LFBB et al (2016) Diclofenac induces proteasome and mitochondrial dysfunction in murine cardiomyocytes and hearts. Int J Cardiol 223:923\u2013935. https:\/\/doi.org\/10.1016\/j.ijcard.2016.08.233","journal-title":"Int J Cardiol"},{"issue":"1","key":"5581_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10557-021-07253-4","volume":"37","author":"PN Thai","year":"2023","unstructured":"Thai PN, Ren L, Xu W et al (2023) Chronic Diclofenac Exposure Increases Mitochondrial Oxidative Stress, Inflammatory Mediators, and Cardiac Dysfunction. Cardiovasc Drugs Ther 37(1):25\u201337. https:\/\/doi.org\/10.1007\/s10557-021-07253-4","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"5581_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/s0891-5849(01)00560-3","volume":"31","author":"EJ Hickey","year":"2001","unstructured":"Hickey EJ, Raje RR, Reid VE et al (2001) Diclofenac induced in vivo nephrotoxicity may involve oxidative stress-mediated massive genomic DNA fragmentation and apoptotic cell death. Free Radic Biol Med 31(2):139\u2013152. https:\/\/doi.org\/10.1016\/s0891-5849(01)00560-3","journal-title":"Free Radic Biol Med"},{"key":"5581_CR7","doi-asserted-by":"publisher","first-page":"101751","DOI":"10.1016\/j.redox.2020.101751","volume":"37","author":"SH Jung","year":"2020","unstructured":"Jung SH, Lee W, Park SH et al (2020) Diclofenac impairs autophagic flux via oxidative stress and lysosomal dysfunction: Implications for hepatotoxicity. Redox Biol 37:101751. https:\/\/doi.org\/10.1016\/j.redox.2020.101751","journal-title":"Redox Biol"},{"issue":"16","key":"5581_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2174\/0113816128304230240327044201","volume":"30","author":"AE Kassab","year":"2024","unstructured":"Kassab AE, Gedawy EM (2024) Recent Advancements in Refashioning of NSAIDs and their Derivatives as Anticancer Candidates. Curr Pharm Des 30(16):1217\u20131239. https:\/\/doi.org\/10.2174\/0113816128304230240327044201","journal-title":"Curr Pharm Des"},{"issue":"9","key":"5581_CR9","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1172\/JCI69741","volume":"123","author":"JR Doherty","year":"2013","unstructured":"Doherty JR, Cleveland JL (2013) Targeting lactate metabolism for cancer therapeutics. J Clin Invest 123(9):3685\u20133692. https:\/\/doi.org\/10.1172\/JCI69741","journal-title":"J Clin Invest"},{"issue":"6","key":"5581_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3892\/etm.2021.10016","volume":"2","author":"l Yang","year":"2021","unstructured":"Yang l, Li J, Li Y et al (2021) Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway. Exp Ther Med 2(6):584. https:\/\/doi.org\/10.3892\/etm.2021.10016","journal-title":"Exp Ther Med"},{"key":"5581_CR11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2174\/0113816128322894241004051814","volume":"31","author":"N Sharma","year":"2025","unstructured":"Sharma N, Bhati A, Aggarwal S et al (2025) PARP Pioneers: Using BRCA1\/2 Mutation-targeted Inhibition to Revolutionize Breast Cancer Treatment. Curr Pharm Des 31:663\u2013673. https:\/\/doi.org\/10.2174\/0113816128322894241004051814","journal-title":"Curr Pharm Des"},{"key":"5581_CR12","doi-asserted-by":"publisher","first-page":"925835","DOI":"10.3389\/fcell.2022.925835","volume":"10","author":"Y Yang","year":"2022","unstructured":"Yang Y, Wu J, Lu W et al (2022) Olaparib, a PARP-1 inhibitor, protects retinal cells from ocular hypertension-associated oxidative damage. Front Cell Dev Biol 10:925835. https:\/\/doi.org\/10.3389\/fcell.2022.925835","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"5581_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/bph.13983","volume":"175","author":"S Korkmaz-Ic\u00f6z","year":"2018","unstructured":"Korkmaz-Ic\u00f6z S, Szczesny B, Marcatti M et al (2018) Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats. Br J Pharmacol 175(2):246\u2013261. https:\/\/doi.org\/10.1111\/bph.13983","journal-title":"Br J Pharmacol"},{"issue":"1","key":"5581_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3892\/ijo.2015.3003","volume":"47","author":"B Arun","year":"2015","unstructured":"Arun B, Akar U, Gutierrez-Barrera AM et al (2015) The PARP inhibitor AZD2281 (Olaparib) induces autophagy\/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Int J Oncol 47(1):262\u2013268. https:\/\/doi.org\/10.3892\/ijo.2015.3003","journal-title":"Int J Oncol"},{"key":"5581_CR15","doi-asserted-by":"publisher","first-page":"107056","DOI":"10.1016\/j.phrs.2023.107056","volume":"200","author":"R Liu","year":"2024","unstructured":"Liu R, Li F, Hao S et al (2024) Low-dose Olaparib improves septic cardiac function by reducing ferroptosis via accelerated mitophagy flux. Pharmacol Res 200:107056. https:\/\/doi.org\/10.1016\/j.phrs.2023.107056","journal-title":"Pharmacol Res"},{"issue":"11","key":"5581_CR16","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1158\/2767-9764.crc-24-0339","volume":"4","author":"ZA Schaaf","year":"2024","unstructured":"Schaaf ZA, Ning S, Leslie AR et al (2024) PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells. Cancer Res Commun 4(11):2976\u20132985. https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0339","journal-title":"Cancer Res Commun"},{"issue":"21","key":"5581_CR17","doi-asserted-by":"publisher","first-page":"11938","DOI":"10.3390\/ijms222111938","volume":"22","author":"LX Zampieri","year":"2021","unstructured":"Zampieri LX, Sboarina M, Cacace A et al (2021) Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells. Int J Mol Sci 22(21):11938. https:\/\/doi.org\/10.3390\/ijms222111938","journal-title":"Int J Mol Sci"},{"issue":"11","key":"5581_CR18","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1002\/1878-0261.70093","volume":"19","author":"NA Yusoh","year":"2025","unstructured":"Yusoh NA, Su L, Chia SL et al (2025) Olaparib synergy screen reveals Exemestane induces replication stress in triple-negative breast cancer. Mol Oncol 19(11):3387\u20133408. https:\/\/doi.org\/10.1002\/1878-0261.70093","journal-title":"Mol Oncol"},{"issue":"8","key":"5581_CR19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1177\/1087057105279635","volume":"10","author":"JM Atienza","year":"2005","unstructured":"Atienza JM, Zhu J, Wang X et al (2005) Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays. J Biomol Screen 10(8):795\u2013805. https:\/\/doi.org\/10.1177\/1087057105279635","journal-title":"J Biomol Screen"},{"issue":"6","key":"5581_CR20","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1111\/febs.16652","volume":"290","author":"A Sarkar","year":"2023","unstructured":"Sarkar A, Dutta S, Sur M et al (2023) Early loss of endogenous NAD(+) following rotenone treatment leads to mitochondrial dysfunction and Sarm1 induction that is ameliorated by PARP inhibition. FEBS J 290(6):1596\u20131624. https:\/\/doi.org\/10.1111\/febs.16652","journal-title":"FEBS J"},{"key":"5581_CR21","doi-asserted-by":"publisher","first-page":"1147414","DOI":"10.3389\/fphar.2023.1147414","volume":"14","author":"J Pei","year":"2023","unstructured":"Pei J, Pan X, Wei G et al (2023) Research progress of glutathione peroxidase family (GPX) in redoxidation. Front Pharmacol 14:1147414. https:\/\/doi.org\/10.3389\/fphar.2023.1147414","journal-title":"Front Pharmacol"},{"issue":"3","key":"5581_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1179\/135100009x392539","volume":"14","author":"S Whillier","year":"2009","unstructured":"Whillier S, Raftos JE, Chapman B et al (2009) Role of N-acetylcysteine and cystine in glutathione synthesis in human erythrocytes. Redox Rep 14(3):115\u2013124. https:\/\/doi.org\/10.1179\/135100009x392539","journal-title":"Redox Rep"},{"issue":"8","key":"5581_CR23","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.2174\/1570159x19666201230144109","volume":"19","author":"G Raghu","year":"2021","unstructured":"Raghu G, Berk M, Campochiaro PA et al (2021) The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Curr Neuropharmacol 19(8):1202\u20131224. https:\/\/doi.org\/10.2174\/1570159x19666201230144109","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"5581_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12964-025-02272-2","volume":"23","author":"TNA Nguyen","year":"2025","unstructured":"Nguyen TNA, Lai HT, Fernandes R et al (2025) Apoptosis-inducing factor (AIF) at the crossroad of cell survival and cell death: implications for cancer and mitochondrial diseases. Cell Commun Signal 23(1):264. https:\/\/doi.org\/10.1186\/s12964-025-02272-2","journal-title":"Cell Commun Signal"},{"issue":"1","key":"5581_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00018-025-05744-3","volume":"82","author":"J Skat-R\u00f8rdam","year":"2025","unstructured":"Skat-R\u00f8rdam J, Lykkesfeldt J, Gluud LL et al (2025) Mechanisms of drug induced liver injury. Cell Mol Life Sci 82(1):213. https:\/\/doi.org\/10.1007\/s00018-025-05744-3","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"5581_CR26","doi-asserted-by":"publisher","first-page":"e56380","DOI":"10.15252\/embr.202256380","volume":"24","author":"BR Desousa","year":"2023","unstructured":"Desousa BR, Kim KK, Jones AE et al (2023) Calculation of ATP production rates using the Seahorse XF Analyzer. EMBO Rep 24(10):e56380. https:\/\/doi.org\/10.15252\/embr.202256380","journal-title":"EMBO Rep"},{"key":"5581_CR27","doi-asserted-by":"publisher","first-page":"116283","DOI":"10.1016\/j.bcp.2024","volume":"228","author":"S Mazumder","year":"2024","unstructured":"Mazumder S, Bindu, Debsharma S, Bandyopadhyay U (2024) Induction of mitochondrial toxicity by non-steroidal anti-inflammatory drugs (NSAIDs): The ultimate trade-off governing the therapeutic merits and demerits of these wonder drugs. Biochem Pharmacol 228:116283. https:\/\/doi.org\/10.1016\/j.bcp.2024","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"5581_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/17425255.2017.1238459","volume":"13","author":"MJ G\u00f3mez-Lech\u00f3n","year":"2017","unstructured":"G\u00f3mez-Lech\u00f3n MJ, Tolosa L, Donato MT (2017) Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing. Expert Opin Drug Metab Toxicol 13(2):137\u2013148. https:\/\/doi.org\/10.1080\/17425255.2017.1238459","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"5581_CR29","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00204-017-2079-6","volume":"92","author":"T Ramirez","year":"2018","unstructured":"Ramirez T et al (2018) Prediction of liver toxicity and mode of action using metabolomics in vitro in HepG2 cells. Arch Toxicol 92(2):893\u2013906. https:\/\/doi.org\/10.1007\/s00204-017-2079-6","journal-title":"Arch Toxicol"},{"issue":"16","key":"5581_CR30","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1111\/febs.17158","volume":"291","author":"A Malla","year":"2024","unstructured":"Malla A, Gupta S, Sur R (2024) Inhibition of lactate dehydrogenase A by diclofenac sodium induces apoptosis in HeLa cells through activation of AMPK. FEBS J 291(16):3628\u20133652. https:\/\/doi.org\/10.1111\/febs.17158","journal-title":"FEBS J"},{"issue":"3","key":"5581_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s0041-008x(03)00368-5","volume":"192","author":"UA Boelsterli","year":"2003","unstructured":"Boelsterli UA (2003) Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 192(3):307\u2013322. https:\/\/doi.org\/10.1016\/s0041-008x(03)00368-5","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"5581_CR32","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s11481-023-10092-9","volume":"18","author":"M Mekhaeil","year":"2023","unstructured":"Mekhaeil M, Conroy MJ, Dev KK (2023) Elucidating the Therapeutic Utility of Olaparib in Sulfatide-Induced Human Astrocyte Toxicity and Neuroinflammation. J Neuroimmune Pharmacol 18(4):592\u2013609. https:\/\/doi.org\/10.1007\/s11481-023-10092-9","journal-title":"J Neuroimmune Pharmacol"},{"issue":"10","key":"5581_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C (2020) Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov 19(10):711\u2013736. https:\/\/doi.org\/10.1038\/s41573-020-0076-6","journal-title":"Nat Rev Drug Discov"},{"key":"5581_CR34","doi-asserted-by":"publisher","unstructured":"Hirst J (2013) Mitochondrial complex I. Annu Rev Biochem. 82:551\u2009\u2013\u200975. https:\/\/doi.org\/10.1146\/annurev-biochem-070511-103700","DOI":"10.1146\/annurev-biochem-070511-103700"},{"issue":"3","key":"5581_CR35","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA et al (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25(3):486\u2013541. https:\/\/doi.org\/10.1038\/s41418-017-0012-4","journal-title":"Cell Death Differ"},{"key":"5581_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jare.2024.04.031","volume":"70","author":"J Zhang","year":"2024","unstructured":"Zhang J, Hu X, Geng Y et al (2024) Exploring the role of parthanatos in CNS injury: Molecular insights and therapeutic approaches. Adv Res 70:271\u2013286. https:\/\/doi.org\/10.1016\/j.jare.2024.04.031","journal-title":"Adv Res"},{"key":"5581_CR37","doi-asserted-by":"publisher","first-page":"106314","DOI":"10.1016\/j.nbd.2023.106314","volume":"187","author":"X Xu","year":"2023","unstructured":"Xu X, Sun B, Zhao C (2023) Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: From pathogenesis to therapeutic opportunities. Neurobiol Dis 187:106314. https:\/\/doi.org\/10.1016\/j.nbd.2023.106314","journal-title":"Neurobiol Dis"},{"issue":"8","key":"5581_CR38","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.3390\/ijms21082767","volume":"21","author":"B Gallyas","year":"2020","unstructured":"Gallyas FJr, Sumegi B (2020) Mitochondrial Protection by PARP Inhibition. Int J Mol Sci 21(8):2767. https:\/\/doi.org\/10.3390\/ijms21082767","journal-title":"Int J Mol Sci"},{"key":"5581_CR39","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.freeradbiomed.2017.04.018","volume":"108","author":"E Hocsak","year":"2017","unstructured":"Hocsak E, Szabo V, Kalman N et al (2017) PARP inhibition protects mitochondria and reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway. Free Radic Biol Med 108:770\u2013784. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2017.04.018","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"5581_CR40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.phrs.2005.02.013","volume":"52","author":"G Graziani","year":"2005","unstructured":"Graziani G, Szab\u00f3 C (2005) Clinical perspectives of PARP inhibitors. Pharmacol Res 52(1):109\u2013118. https:\/\/doi.org\/10.1016\/j.phrs.2005.02.013","journal-title":"Pharmacol Res"},{"issue":"3","key":"5581_CR41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1053\/jhep.2002.31871","volume":"35","author":"Y Masubuchi","year":"2002","unstructured":"Masubuchi Y, Nakayama S, Horie T (2002) Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 35(3):544\u2013551. https:\/\/doi.org\/10.1053\/jhep.2002.31871","journal-title":"Hepatology"},{"key":"5581_CR42","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.toxrep.2023.10.001","volume":"11","author":"C Boonyong","year":"2023","unstructured":"Boonyong C, Jianmongkol S (2023) Predicting molecular mechanism of silymarin-potentiated diclofenac toxicity: Insight from in silico molecular docking. Toxicol Rep 11:339\u2013345. https:\/\/doi.org\/10.1016\/j.toxrep.2023.10.001","journal-title":"Toxicol Rep"},{"issue":"1","key":"5581_CR43","doi-asserted-by":"publisher","first-page":"e202313520","DOI":"10.1085\/jgp.202313520","volume":"157","author":"E Murphy","year":"2025","unstructured":"Murphy E, Eisner DA (2025) How does mitochondrial Ca2\u2009+\u2009change during ischemia and reperfusion? Implications for activation of the permeability transition pore. J Gen Physiol 157(1):e202313520. https:\/\/doi.org\/10.1085\/jgp.202313520","journal-title":"J Gen Physiol"},{"issue":"8","key":"5581_CR44","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/s41418-023-01187-0","volume":"30","author":"P Bernardi","year":"2023","unstructured":"Bernardi P, Gerle C, Halestrap AP et al (2023) Identity, structure, and function of the mitochondrial permeability transition pore: controversies, consensus, recent advances, and future directions. Cell Death Differ 30(8):1869\u20131885. https:\/\/doi.org\/10.1038\/s41418-023-01187-0","journal-title":"Cell Death Differ"},{"issue":"6","key":"5581_CR45","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3390\/biom12060788","volume":"12","author":"SS Santos","year":"2022","unstructured":"Santos SS, Brunialti MKC, Rodrigues LOCP et al (2022) Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress. Biomolecules 12(6):788. https:\/\/doi.org\/10.3390\/biom12060788","journal-title":"Biomolecules"},{"issue":"1","key":"5581_CR46","doi-asserted-by":"publisher","first-page":"18699","DOI":"10.1038\/s41598-019-55296-3","volume":"9","author":"R Shiratori","year":"2019","unstructured":"Shiratori R, Furuichi K, Yamaguchi M et al (2019) Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner. Sci Rep 9(1):18699. https:\/\/doi.org\/10.1038\/s41598-019-55296-3","journal-title":"Sci Rep"},{"issue":"6","key":"5581_CR47","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3892\/etm.2021.10016","volume":"21","author":"L Yang","year":"2021","unstructured":"Yang L, Li J, Li Y et al (2021) Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway. Exp Ther Med 21(6):584. https:\/\/doi.org\/10.3892\/etm.2021.10016","journal-title":"Exp Ther Med"},{"issue":"10","key":"5581_CR48","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc.2017.77","volume":"17","author":"C Corbet","year":"2017","unstructured":"Corbet C, Feron O (2017) Tumour acidosis: from the passenger to the driver\u2019s seat. Nat Rev Cancer 17(10):577\u2013593. https:\/\/doi.org\/10.1038\/nrc.2017.77","journal-title":"Nat Rev Cancer"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05581-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:24:26Z","timestamp":1784276666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-026-05581-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["5581"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05581-3","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}